Alekseeva M L, Andreeva E N, Novikov E A, Fanchenko N D, Seliverstov A A, Bobkova M V, Margiani F R
Akush Ginekol (Mosk). 1995(5):25-8.
Tumor markers CA 125, CA 19-9, and carcinoembryonic antigen (CEA) were measured in the blood sera of 396 inpatients of different age. In 139 patients the measurements were carried out over time. Hoffman La Roche enzyme immunoassay test kits were used. Eight groups of women were tested: controls without gynecological diseases, women in need of plastic repair of the genitals, patients with inflammatory diseases, with cervical endometriosis, internal endometriosis, ovarian endometriosis, uterine myoma, benign ovarian tumors, and malignant tumors of the ovaries. The results indicate a relatively high diagnostic value of measuring CA 125 in gynecological patients, particularly in those with endometriosis. Parallel measurements of three markers in the blood serum (CA 125, CA 19-9, and CEA) are more informative for the differential diagnosis of endometriosis and malignant tumors. Follow-up of CA 125 concentration may be used to assess the efficacy of therapy and help early detect the disease recurrences.
对396名不同年龄段住院患者的血清进行了肿瘤标志物CA 125、CA 19-9和癌胚抗原（CEA）检测。对其中139名患者进行了长期检测。使用了罗氏酶免疫分析检测试剂盒。对八组女性进行了检测：无妇科疾病的对照组、需要生殖器整形修复的女性、患有炎症性疾病、宫颈子宫内膜异位症、内在性子宫内膜异位症、卵巢子宫内膜异位症、子宫肌瘤、卵巢良性肿瘤和卵巢恶性肿瘤的患者。结果表明，检测CA 125对妇科患者具有较高的诊断价值，尤其是对子宫内膜异位症患者。血清中三种标志物（CA 125、CA 19-9和CEA）的联合检测对子宫内膜异位症和恶性肿瘤的鉴别诊断更具信息价值。对CA 125浓度的随访可用于评估治疗效果并有助于早期发现疾病复发。
